Women seeking cosmetic eyelid surgery in the United Kingdom are increasingly turning to unregulated practitioners operating from residential properties, raising serious safety concerns among medical experts and campaigners. An investigation has uncovered a network of so-called “scalpel sharks” performing procedures such as blepharoplasty—eyelid surgery designed to remove excess skin and improve appearance—for significantly lower costs than licensed clinics, often at considerable risk to patients’ health.
One operator identified is Luyen Vu, also known by nicknames including Miss Cindy and the Bleph Lady, who carries out eyelid and facelift surgeries from domestic settings in Manchester. These procedures typically cost around £850 for blepharoplasty, less than half the price charged by reputable providers. Vu has no known medical qualifications or registration, yet advertises her services as “professional cosmetic surgery” in supposedly sterile environments, promising aftercare including antibiotics.
Women who have undergone surgery with Vu report severe complications including extensive scarring, asymmetry, and disfigurement. Some have described being left unable to fully close their eyes due to excessive removal of eyelid skin, a condition that can cause chronic discomfort and potential vision impairment. Many patients say they have struggled to obtain follow-up care or compensation after Vu disappears or changes locations to avoid scrutiny.
These unregulated operations exploit a legal loophole that allows individuals to perform cosmetic surgery so long as they do not falsely claim medical qualifications. This gap has contributed to a rise in unsafe cosmetic procedures performed outside approved clinics, with critics warning this has created a “wild west” where thousands of unlicensed operators put patients at risk. Experts estimate that for every legitimate practitioner, there may be as many as four unregulated operators carrying out procedures.
Campaign groups say the burden of complications disproportionately falls on the National Health Service, which often must provide corrective surgery and ongoing care when treatments go wrong. Advocates have repeatedly called for stricter regulations and enforcement to protect consumers from harmful practices, but say government action has been slow.
Vu is believed to collaborate with established beauty clinics such as Fleek Aesthetics in Manchester, whose proprietor Cheryl Hogan promotes Vu’s work on social media platforms despite acknowledging Vu’s lack of medical registration. Hogan has been accused of intimidating victims who speak out, deterring some from pursuing legal action or media engagement.
Medical professionals caution that while legitimate blepharoplasty is generally low risk when performed in appropriate clinical settings, unregulated procedures carry heightened dangers including infection, scarring, and impaired eyelid function. Consultant ophthalmic surgeon Dr. Elizabeth Hawkes emphasized the risks posed by surgery performed in unsanitary environments without adequate aftercare, warning of potential permanent vision loss.
This issue is not isolated to Vu alone; other unlicensed providers such as The Clinic Club—a group with ties to disqualified beauty consultant Ricky Sawyer—have also faced allegations of botched procedures and patient harm. Government bodies face increasing pressure to introduce comprehensive bans on high-risk cosmetic interventions unless delivered by qualified professionals.
A Department of Health and Social Care spokesperson acknowledged the devastation caused by unsafe cosmetic surgery and urged prospective patients to verify qualifications and avoid suspiciously cheap treatments. Despite promises to close regulatory loopholes, investigations indicate that operators like Vu continue to evade enforcement by frequently relocating and exploiting informal marketing channels.
As the demand for cosmetic enhancements grows, health officials and campaigners warn that without stronger safeguards and robust legal frameworks, vulnerable individuals will remain at risk from unregulated operators who prioritize profit over patient safety.